ç®èç§æ²»çè¬äŒç€Ÿã§ãã Verrica Pharmaceuticals Inc. ã¯ãç±³åœã§ç®èçŸæ£æ£è
åãã®æ²»çè¬ã®éçºãšè²©å£²ãè¡ã£ãŠããŸããå瀟ã®äž»å補ååè£ã«ã¯ãäŒææ§è»å±è
«ã®æ²»çè¬ VP-102 ããããŸããããã¯å°åžžæ§ç£èŽ
ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšãå®äºããŠããã倿§åšç£èŽ
ã®æ²»çè¬ãšããŠç¬¬ II çžèšåºè©Šéšã宿œäžã§ãããŸããè¶³åºç£èŽ
ã®æ²»çè¬ãšããŠã«ã³ã¿ãªãžã³ããŒã¹ã®è£œååè£ VP-103 ãéçºäžã§ããå瀟ã¯ãVP-102 ãå«ãäŒææ§è»å±è
«ããã³å°åžžæ§ç£èŽ
ã®æ²»çè¬åè£ã®æ¥æ¬ã§ã®éçºãšè²©å£²ã«é¢ããŠé³¥å±
è¬åæ ªåŒäŒç€Ÿãšã©ã€ã»ã³ã¹ããã³ææºå¥çŽãçµãã§ããŸãããŸããç®èè
«çåŠã®é©å¿çåãã« LTX-315 ãéçºããã³è²©å£²ããã©ã€ã»ã³ã¹å¥çŽã Lytix Biopharma AS ãšçµãã§ããŸããVerrica Pharmaceuticals Inc. 㯠2013 幎ã«èšç«ããããã³ã·ã«ããã¢å·ãŠã§ã¹ããã§ã¹ã¿ãŒã«æ¬ç€Ÿã眮ããŠããŸãã